Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Pfizer’s oncology R&D strategy: Jeff Legos on speed, breadth and novel combinations

Pfizer’s oncology R&D strategy: Jeff Legos on speed, breadth and novel combinations

  • March 4, 2026

After steering positive key pivotal readouts for a trio of Novartis’ blockbusters, Jeff Legos is now tasked with fleshing out Pfizer’s $43 billion Seagen acquisition into an antibody-drug conjugate empire while accelerating a PD-1xVEGF bispecific licensed from 3SBio toward 2028 readouts amid heated competition.

Leave A Comment

Fields (*) Mark are Required